IPE JC88
DEC 09 2004
PATENT & TRADEMARK OFFICE

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
BLONDELET--ROUAULT, et al.

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: **10/680,860**

Filed: **October 7, 2003**

Title: **POLYPEPTIDES INVOLVED IN THE BIOSYNTHESIS OF SPIRAMYCINS, NUCLEOTIDE SEQUENCE ENCODING THESE POLYPEPTIDES AND APPLICATIONS THEREOF**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 7, 2004
Date of Deposit

Jonas Pierre, Sr.
Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**3737**
Telefax (908) 231-2626
Aventis Docket No. FRAV2002/0028 US NP

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC88
DEC 0 9 2004
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/680,860
Filing Date	10-07-2003
First Named Inventor	BLONDELET-ROUAULT, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	FRAV2002/0028 - US - NP

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,098,837		BECKMANN, et al.	03-24-1992	
		5,240,849		ARISAWA, et al.	08-31-1993	
		5,322,937		ARISAWA, et al.	06-21-1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP	0 346 000		BECKMANN, et al.	12-13-1989		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC88 DEC 09 2004 PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/680,860
Filing Date	10-07-2003
First Named Inventor	BLONDELET-ROUAULT, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	FRAV2002/0028 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	/	ARISAWA, Akira et al., Cloning and Nucleotide Sequences of Two Genes Involved in the 4"-O-Acylation of Macrolide Antibiotics from Streptomyces thermotolerans, Bioscience, Biotechnology, and Biochemistry, (1993), Vol. 57, No. 12, pp. 2020 - 2025	
	/	ARISAWA, Akira et al., Cloning of the Macrolide Antibiotic Biosynthesis Gen acyA, Which Encodes 3-O-Acyltransferase, from Streptomyces thermotolerans and Its Use for Direct Fermentative Production of a Hybrid Macrolide Antibiotic, Applied and Environmental Microbiology, (1994), Vol. 60, No. 7, pp. 2657 - 2660	
	/	ARISAWA, Akira et al., Nucleotide Sequence Analysis of the Carbomycin Biosynthetic Genes Including the 3-O-Acyltransferase Gene from Streptomyces thermotolerans, Biosci. Biotech. Biochem, (1995), Vol. 59, No. 4, pp. 582 - 588	
	/	BATE, Neil et al., Multiple regulatory genes in the tylosin biosynthetic cluster of Streptomyces fradiae, Chemistry & Biology, (1999), Vol. 6, No. 9, pp. 617 - 624	
	/	BATE, Neil et al., The mycarose-biosynthetic genes of Streptomyces fradiae, producer of tylosin, Microbiology, (2000), Vol. 146, pp. 139 - 146	
	/	GANDECHA, Atul R. et al., Analysis of four tylosin biosynthetic genes from the tylLM region of the Streptomyces fradiae genome, Gene, (1997), Vol. 184, pp. 197 - 203	
	/	GOURMELEN, Anne et al., Characterization of a Glycosyl Transferase Inactivating Macrolides, Encoded by gimA from Streptomyces ambofaciens, Antimicrobial Agents and Chemotherapy, (1998), Vol. 42, No. 10, pp. 2612 - 2619	
	/	OMURA, Satoshi et al., Bioconversion and Biosynthesis of 16-Membered Macrolide Antibiotics. X. Final Steps in the Biosynthesis of Spiramycin, using Enzyme Inhibitor: Cerulenin, Chemical & Pharmaceutical Bulletin, (1979), Vol. 27, No. 1, pp. 176 - 182	
	/	OMURA, Satoshi et al., Isolation and Properties of Spiramycin I 3-Hydroxyl, Journal of Biochemistry, (1979), Vol. 86, pp. 1753 - 1758	
		PERNODET, Jean-Luc et al., Dispensable ribosomal resistance to spiramycin conferrd by srmA in the spiramycin producer Streptomyces ambofaciens, Microbiology, (1999), Vol. 145, pp. 2355 - 2364	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JC88
DEC 09 2004
PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/680,860
Filing Date	10-07-2003
First Named Inventor	BLONDELET-ROUAULT, et al.
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	FRAV2002/0028 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	PERNODET, Jean-Luc et al., Resistance to spiramycin in Streptomyces ambofaciens, the producer organisms, involves at least two different mechanisms, Journal of General Microbiology, (1993), Vol. 139, pp. 1003 - 1011	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.